ADMdx presents advances at the Alzheimer’s Association International Conference in Toronto, July 26 and 27. ADMdx will present three posters at the conference: Measurement of Amyloid Burden Using the Early Frames of Amyloid PET and a Multivariate Classifier” and “Combining Neurodegenerative Characterization with Amyloid Burden Measurement Using an Early Frame Amyloid PET Multivariate Classifier”. The first presentation demonstrates application of ADMdx classifier technology to the first few minutes of an amyloid scan to measure neurodegeneration, enabling better patient characterization and prediction of clinical worsening for stratification. The second presentation introduces novel ADMdx technology allowing detection of amyloid burden during the first 20 minutes of a PET scan, in contrast to current 50 – 70 minute wait times.
Our CTO, Dr. Miles Wernick, was interviewed by Crain’s Chicago Business about how ADMdx was started and its technology to diagnose and predict dementia.
ADMdx publishes work demonstrating the potential of ADMdx image analysis technology to detect Alzheimer’s disease and treatment effects in at-risk, enriched populations. Adults with Down Syndrome (DS) provide a potentially enriched population for the preclinical and prodromal evaluation of Alzheimer’s disease (AD) therapeutics due to their accelerated rate of amyloid plaque formation and development of AD. However, conducting clinical trials in this population requires the ability to identify subjects with a known stage of AD, as well as the capability to detect AD-specific treatment effects distinct from those upon DS. ADMdx technology has achieved differentiation of AD from DS within subjects using either MRI or FDG PET imaging, enabling study of AD interventional treatments. Work was performed in collaboration with Dr. Michael Rafii of the University of California, San Diego and the Alzheimer’s Disease Cooperative Study (ADCS). This work has been published in the June 2016 issue of Alzheimer’s & Dementia: Translational Research and Clinical Intervention.
ADMdx awarded Phase IIB SBIR grant from the National Science Foundation. The grant provides funding to further our development of a multi-modality Alzheimer’s Disease Progression Classifier, which stages preclinical through dementia AD patients and predicts clinical trajectory, and a Dementia Classifier, which distinguishes different types of dementia.
